GT Biopharma (GTBP) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma (GTBP) has outperformed Senti Biosciences (SNTI) over the past year, gaining 789.5% versus a loss of 83.5%. Over five years, GTBP leads with a -96.7% price change compared with -99.7% for SNTI. GT Biopharma is the larger company by market cap ($12.1 million vs $9.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GTBP | SNTI |
|---|---|---|
| Share price | $6.68 | $0.3144 |
| Market cap | $12.05M | $9.79M |
| 1-day change | +12.27% | -2.27% |
| YTD return | +750.96% | -69.77% |
| 1-year return | +789.48% | -83.45% |
| 5-year return | -96.72% | -99.68% |
| EPS (TTM) | $-147.50 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.75 | $2.88 |
| 52-week low | $4.91 | $0.29 |
| Distance from 52-week high | -76.77% | -89.08% |
| Analyst consensus | none | none |
| Avg. price target upside | +1022.75% | +4193.89% |
| Average volume | 55.52K | 573.78K |
| Shares outstanding | 1.80M | 31.15M |
| Employees | 1 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed SNTI by 872.9 percentage points over the past year.
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
GTBP vs SNTI FAQ
Which is bigger, GT Biopharma or Senti Biosciences?
GT Biopharma (GTBP) is larger, with a market capitalization of $12.05M compared with $9.79M for Senti Biosciences (SNTI).
Which stock has performed better over the past year, GTBP or SNTI?
GTBP returned +789.48% over the past 12 months, compared with -83.45% for SNTI (price return, excluding dividends). Past performance does not predict future results.
Are GT Biopharma and Senti Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for GT Biopharma and Biotechnology: Biological Products (No Diagnostic Substances) for Senti Biosciences.